Citius Pharmaceuticals (CTXR) Net Income Attributable to Noncontrolling Interests (2024 - 2026)
Citius Pharmaceuticals (CTXR) posted Net Income Attributable to Noncontrolling Interests of -$3.06 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), compared with -$414,000 a year earlier.
Powered by 
Analysis
Citius Pharmaceuticals (CTXR) Net Income Attributable to Noncontrolling Interests (2024 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Net Income Attributable to Noncontrolling Interests at Citius Pharmaceuticals was -$11.89 million; for FY2025 (ended Sep 30, 2025), it came in at -$2.31 million.
- In prior fiscal years, Citius Pharmaceuticals' Net Income Attributable to Noncontrolling Interests was -$287,000 in FY2024.
- Quarterly Net Income Attributable to Noncontrolling Interests has run from a low of -$6.88 million in fiscal Q2 2026 to a high of -$414,000 in fiscal Q3 2025 over five years.
- According to Business Quant data, Net Income Attributable to Noncontrolling Interests for the three prior fiscal quarters was -$6.88 million (Q2 2026), -$1.17 million (Q1 2026) and -$784,358 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | - |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | - |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Citius Pharmaceuticals | 13.45 Mn | -10.82 Mn | 1.00 Mn | -3.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.06 Mn |
| Mar 31, 2026 | -6.88 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Jun 30, 2025 | -414,000.00 |
| Mar 31, 2025 | -595,000.00 |
| Dec 31, 2024 | -513,000.00 |
API Access
Citius Pharmaceuticals Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=CTXR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "CTXR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=CTXR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();